<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230517058216N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-27</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Comparison Efficacy of platelet-rich fibrin membrane and melatonin on sensory recovery following mandibular fracture</public_title>
      <acronym></acronym>
      <scientific_title>Comparison Efficacy of platelet-rich fibrin membrane and melatonin on sensory recovery following mandibular fracture: a double-blind randomized trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70987</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be divided into three groups according to the permutation block randomization method. Based on the permutation blocks method, 5 blocks of 9 blocks are considered for randomizing the samples in three groups. The randomization method of permutation blocks is based on random blocks with the same size, and random allocation 1 software is used to create random blocks. Based on the output of the software, based on each block of size 9, a number from 1 to 9 that represents the block number is randomly selected and then according to the assigned groups in each block, randomization of the samples in the order of entering The study is based on the specified intervention, Blinding description: This study is double-blind, and the examiner who performs the post-operative examinations and completes the checklist and the patient are blind to the type of intervention. For all patients, the study process, including how to prepare platelet-rich fibrin from the patient's blood sample in the first group, and the use of melatonin in the second group, are described. However, which group the patient will be placed in is determined during the sampling process and based on randomization.</study_design>
      <phase>3</phase>
      <hc_freetext>Lower lip and chin paresthesia due to mandibular fracture.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In group 1, after exposing the fracture area, in cases of involvement of the lower alveolar canal, PRF prepared from the patient's blood is placed inside the bone and on the canal, and then bone reduction and fixation are performed by miniplates and mono-cortical screws. In cases of exposure of the mental nerve, the fibrin membrane is placed directly on the nerve in the exit area of ​​the foramen and is supported by an absorbable collagen membrane and absorbable suture. Intervention 2: Intervention group: In group 2, 10 mg melatonin capsules (Galinos-Iran) were given to the patients the night before surgery and then one capsule every night until 21 days after surgery. Patients who undergo IMF after surgery dissolve the contents of the capsule in a glass of water and drink it. Reduction and fixation of fracture lines will be done as in group 1. Intervention 3: Control group: In group 3, reduction and fixation of fracture lines will be performed as the control group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be shared transparently.

When:
The access period starts 6 months after the results are published.

To whom:
All researchers and practitioners in related industry to the study title.

Conditions:
Data use or analysis is permitted with the permission of the research investigators

Where to obtain:
Mohammad Goodarzi
E-mail :m.goodarzi.omfs@gmail.com

How to obtain:
By sending an email to the researcher, the documentation plan will be sent to them within a month.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Goodarzi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Maxillofacial Surgery, Shahid Rahnamon Hospital,  Farrokhi Street, Yazd</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8913814396</zip>
        <telephone>+98 35 3312 2002</telephone>
        <email>m.goodarzi.omfs@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza Navab Azam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Maxillofacial Surgery, Shahid Rahnamon Hospital,  Farrokhi Street, Yazd</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8913814396</zip>
        <telephone>+98 35 3312 2002</telephone>
        <email>alirezanavabazam266@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients whit no  history of systemic diseases such as diabetes, kidney and liver problems
Patients with no  history of sensitivity to melatonin
Patients who have informed consent to participate in the study
Patients who have no history of previous mandibular surgery and nerve damage
Patients with minimally displaced fractures that require open treatment of the mandible
Patients with a level of GCS of 15, who are fully awake for examinations</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who have dissected nerve fibers at the fracture site
Patients who have soft tissue injuries in the lower lip and chin area.
Patients with mental retardation and psychotic disorders who do not cooperate for examinations
Patients with blood and coagulation disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Disturbances of skin sensation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In group 1, after exposing the fracture area, in cases of involvement of the lower alveolar canal, PRF prepared from the patient's blood is placed inside the bone and on the canal, and then bone reduction and fixation are performed by miniplates and mono-cortical screws. In cases of exposure of the mental nerve, the fibrin membrane is placed directly on the nerve in the exit area of ​​the foramen and is supported by an absorbable collagen membrane and absorbable suture.</i_keyword>
      <i_keyword>Intervention group: In group 2, 10 mg melatonin capsules (Galinos-Iran) were given to the patients the night before surgery and then one capsule every night until 21 days after surgery. Patients who undergo IMF after surgery dissolve the contents of the capsule in a glass of water and drink it. Reduction and fixation of fracture lines will be done as in group 1</i_keyword>
      <i_keyword>Control group: In group 3, reduction and fixation of fracture lines will be performed as the control group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Improving the amount of lower lip paresthesia caused by mandibular fracture. Timepoint: One week, one month and three months. Method of measurement: Two-point discrimination, brush direction detection and self-expression (Visual Analogue Scale) tests.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-12</approval_date>
        <contact_name>Ethics Committee of Shahid Sadoughi University of Medical Sciences, Yazd</contact_name>
        <contact_address>Central Organization of Shahid Sadoughi University of Medical Sciences and Health Services, Shahid Bahonar square, Yazd Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
